CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients

Wotan Zeng1†, Yali Guo2†, Peixian Chen3, Zhike Liu4, Dafang Chen4, Chunji Han5*

1Department of Physiology and Pathophysiology, College of Medicine, Yanbian University, Yanji, Jilin Province, 2Department of Endocrinology, Central Hospital of Shenzhen Guangming New District, Shenzhen, 3Medical College, Shantou, Guangdong Province, 4Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, and 5Department of Immunology and Pathogenic Biology, College of Medicine, Yanbian University, Yanji, Jilin Province, China

Keywords
CYP2C9*, Gliclazide, Type 2 diabetes mellitus

*Correspondence
Chunji Han
Tel.: +86-433-2435076
Fax: +86-433-2732140
E-mail address: cjhan@ybu.edu.cn

J Diabetes Investig 2016; 7: 764–768
doi: 10.1111/jdi.12486

ABSTRACT
Aims/Introduction: The objective of the present study was to investigate the effects of CYP2C9*3 polymorphisms on the therapeutic response to gliclazide in type 2 diabetes patients.

Materials and Methods: A total of 746 incident type 2 diabetes patients were included in this study. After enrolment, patients went on 4-week gliclazide monotherapy. Fasting plasma glucose was measured before and after treatment. Hypoglycemia episodes and lifestyle information were collected by weekly follow up. Genotyping of rs1057910 was carried out using the single base primer extension method. The t-test, analysis of variance and chisquare-test were used to evaluate the effects of rs1057910 alleles on the therapeutic response to gliclazide.

Results: After the therapy, fasting plasma glucose decreased significantly from 11.2 ± 2.7 mmol/L to 8.0 ± 2.2 mmol/L (P < 0.001). Patients with AC/CC genotypes of rs1057910 had a greater reduction of fasting plasma glucose (3.6 vs 3.0 mmol/L, P < 0.001; 31.4 vs 24.5%, P < 0.001) and a higher rate of treatment success (54.7 vs 37.5%, P < 0.001; 51.4 vs 32.3%, P < 0.001; 71.6 vs 48.3%, P < 0.001 for criterion 1, 2 and 3, respectively).

Conclusions: The present study showed that the polymorphism at rs1057910 significantly affected the therapeutic response of gliclazide in type 2 diabetes mellitus patients. The risk allele is associated with a greater decrease of fasting blood glucose and a higher rate of treatment success with gliclazide monotherapy.

INTRODUCTION
Sulfonylureas (SUs) have been a cornerstone of type 2 diabetes mellitus pharmacotherapy for over 50 years, and are among the most widely used oral hypoglycemic agents1,2. They work by stimulating the secretion of insulin from pancreatic β-cells3. It is well recognized that a substantial interindvidual variability exists in the response to SUs1. In addition to some environmental factors, such as age, sex, disease status, drug and food interactions, and comorbidity4, genetic polymorphisms in the gene coding for enzymes involved in the metabolism of SUs play an important role in the therapeutic response among individuals.

Most SUs are intensively metabolized in the liver, and cytochrome P450 (CYP) 2C9 is a major enzyme mediating the metabolism of SUs4. Previous studies in healthy volunteers have shown that the polymorphisms in the CYP2C9 gene seriously affected the catalytic capacity of the enzyme5–9. The most common CYP2C9 variant alleles, namely CYP2C9*3 (rs1057910), are responsible for the majority of poor metabolizer phenotype5,7,10–12.

A few studies have assessed the effects of rs1057910 on the response to SUs in type 2 diabetes13–21. However, most of them merely focused on an adverse effect, hypoglycemia, and scarce evidence exists to support a better therapeutic response as a result of this common variant. Meanwhile, because of limited sample size, different study designs and outcome definitions, these studies yielded controversial results. In the present...
prospective study, we aimed to investigate the association between rs1057910 and the efficacy as well as adverse effect of gliclazide in Chinese type 2 diabetes patients.

MATERIALS AND METHODS
Study design and patient selection
The present study was carried out in the outpatient clinic of the Second Affiliated Hospital of Shantou University Medical College. Type 2 diabetes was diagnosed according to the World Health Organization criterion\(^2\). Patients were eligible for the study if they were newly diagnosed patients with type 2 diabetes and could not attain an appropriate fasting plasma glucose level (fasting plasma glucose [FPG] <7.8 mmol/L) through lifestyle modification, and drug-naive patients. Patients with any acute or chronic diabetes complications, malignancies, endocrine disorders, myocardial infarction or heart failure, chronic gastrointestinal disease or liver dysfunction, renal insufficiency, systemic inflammatory disease, surgery and corticosteroids treatment were excluded. Pregnant and lactating women were also excluded. This study was approved by the ethics committee of Shantou University Medical College. Written informed consent to this study was obtained from all participants.

After enrolment, all the participants started 4-week treatment with gliclazide (Tianjin HuaJin Pharmaceutical Company, Tianjin, China). The initial dose of gliclazide was 40 mg twice daily (half an hour before breakfast and supper). The dosage was adjusted according to FPG at the 15th day. Another 40 mg was added when FPG was ≥7.0 mmol/L.

At the first visit, an experienced physician completed a questionnaire for each participant to collect information on demographic characteristics, medical history and medication, and lifestyle factors (including diet, exercise, smoking and alcohol consumption). Anthropometric parameters, such as height, weight, waist circumference, hip circumference and blood pressure, were measured according to standard protocols. An overnight (>10 h) fasting blood sample was drawn for determination of FPG, lipid profile, liver and renal function, and routine blood cell counts. Diabetes education including a brief introduction to type 2 diabetes, as well as advice on diet and exercise, was provided to all participants.

Participants came back for clinical follow up every 2 weeks. A clinical follow-up questionnaire was implemented by a trained physician for each participant to monitor their medication compliance, diet, exercise and side-effects. FPG was measured at each clinical follow up. At day 8 and day 22, a call was made by the same physician to complete a questionnaire about the medication compliance, diet, exercise and side effects for each participant.

Laboratory methods
Plasma glucose was profiled by the glucose oxidase method. Lipid profile, and liver and renal function were tested using an automatic biochemical analyzer. Genomic deoxyribonucleic acid was isolated from peripheral blood leukocytes using the method of protein precipitation according to standard procedures. Genotyping of rs1057910 and rs1799853 were carried out using the GenomeLab SNP stream Genotyping System (Beckman Coulter Inc., Fullarton, CA, USA) according to the manufacturer’s instructions\(^2\). Only data from rs1057910 was analyzed as a result of the low frequency of the minor allele for the rs1799853 (the genotype frequency of CC, CT, and TT are 99.6, 0.40 and 0%, respectively).

Definition of outcomes
Three kinds of outcomes were used in the present study to evaluate the effects of rs1057910 alleles on the therapeutic response to gliclazide. The primary outcome for this study was the decrease of FPG at day 29 (both absolute and percentage value of the FPG reduction). The second outcome was the success of the gliclazide treatment. As for this outcome, we used three criteria to compare with other studies. They were as follows: (i) FPG <7.8 mmol/L at day 29, this was the same as another study from China\(^2\); (ii) FPG <7.0 mmol/L, this was the same as the study of Ren et al.\(^2\); and (iii) FPG <7.2 mmol/L and FPG ≥3.9 mmol/L, this was in line with the China Guideline for type 2 diabetes\(^2\). We also compared the number of hypoglycemia episodes among different genotypes of rs1057910. Hypoglycemia in the present study was ascertained by self-report. A hypoglycemia episode was ascertainment if any of the following symptoms occurred: palpitations, tremor, sweating, hunger, anxiety, behavioral changes, difficulty in concentrating and thinking, confusion, cognitive impairment, convulsions, and coma\(^2\).

Statistical analysis
Continuous variables were presented as mean ± standard deviation, and compared by t-test or ANOVA among groups. The frequency distributions of categorical variables among groups were compared by Pearson’s chisquare-test. SAS for Windows version 9.1 (SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses.

RESULTS
A total of 746 type 2 diabetes patients were available for data analysis in the present study. The frequencies of rs1057910 genotype AA, AC, and CC were 90.08, 9.65 and 0.27%, respectively. The allele frequencies were in Hardy–Weinberg equilibrium. There were no significant differences in age, sex, body mass index, rice intake, sugar intake and exercise time among the genotype at baseline (Table 1).

Participants in the present study performed good management of their diet and exercise behavior during the follow-up period. Compared with day 1, the frequency of non-sugar intake at day 29 was significantly increased (P < 0.001), while there was no significant difference in the rice intake (P = 0.440) and exercise time (P = 0.184). After 4 weeks of gliclazide treatment, the FPG decreased significantly from...
11.2 ± 2.7 mmol/L to 8.0 ± 2.2 mmol/L (P < 0.001). These results are shown in Table 2.

Table 3 shows the association between the rs1057910 genotype and therapeutic response to gliclazide. Owing to the low frequency of CC genotype for rs1057910, pooling individuals with AC and CC genotype was carried out in the association analysis. Patients with AC and CC genotypes had greater reduction of FPG (3.6 vs 3.0 mmol/L, P < 0.001; 31.4 vs 24.5%, P < 0.001), and a higher rate of treatment success (54.7% vs 37.5%, P < 0.001; 71.6 vs 48.3%, P < 0.001; 31.4 vs 24.9%, P < 0.001), and a higher rate of treatment success (54.7% vs 37.5%, P < 0.001; 71.6 vs 48.3%, P < 0.001; 31.4 vs 24.9%, P < 0.001). These interindividual differences in the dose–response relationship for gliclazide, both with respect to the glucose and the insulin response were observed. Monitoring of gliclazide plasma concentrations has therefore been proposed to reduce the cases of individual toxicity or lack of efficacy caused by relative overdosage or underdosage, respectively. A reduction in variability of plasma concentrations could be achieved if homozygous and heterozygous carriers of CYP2C9 allele *3 received lower doses. It is common sense in clinical pharmacology that a reduction in the variability of dose–concentration relationships could result in more predictable efficacy and lower incidence of adverse events. To achieve similar plasma concentration profiles, slow metabolizers (genotype CYP2C9*3/*3) should receive less than 50% of the dose that is adequate for rapid metabolizers. Carriers of the *3/*3 genotype of CYP2C9 might have a substantially higher rate of drug accumulation, particularly when a twice-daily dosing scheme is applied. Therefore, it is logical to hypothesize that patients with *3 alleles will have a lower clearance of SUs and a higher plasma SU levels, and this will eventually produce a better therapeutic response and a greater risk for hypoglycemia.

The existing evidence around a better therapeutic response of SUs as a result of CYP2C9 polymorphisms is scarce and inconclusive. A population pharmacogenetic study of incident sulfonylurea users found that type 2 diabetes patients with CYP2C9*2/*2, *2/*3, or *3/*3 genotypes were 3.4-fold (P = 0.0009) more likely to achieve a treatment hemoglobin A1C level <7% than patients with two wild-type CYP2C9 alleles, and this corresponded to a 0.5% (P = 0.003) greater reduction in hemoglobin A1C concentration. Another prospective study

| Variable | Rs1057910 |
|----------|-----------|
|          | AA (n = 672) | AC (n = 72) | CC (n = 2) |
| Age, years (SD) | 495 ± 8.2 | 503 ± 7.6 | 53.7 ± 6.9 |
| BMI, kg/m² (SD) | 247 ± 3.0 | 249 ± 2.8 | 250 ± 2.1 |
| Male (%) | 402 (59.8) | 45 (62.5) | 1 (50.0) |
| FPG, mmol/L (SD) | 113 ± 2.8 | 110.0 ± 2.6 | 105.5 ± 1.1 |
| Duration of diabetes, years (SD) | 1.26 ± 2.6 | 1.29 ± 2.1 | 1.23 ± 1.7 |
| Rice, g/day (SD) | 370 ± 130 | 370 ± 135 | 325 ± 65 |
| Exercise time, h/day (SD) | 0.9 ± 0.7 | 0.8 ± 0.7 | 0.5 ± 0.6 |
| Sugar | | | |
| None (%) | 455 (67.7) | 52 (72.3) | 2 (100.0) |
| 1–2/week (%) | 162 (24.2) | 14 (19.4) | 0 (0) |
| 3/week (%) | 55 (8.1) | 6 (8.3) | 0 (0) |

BMI, body mass index; FPG, fasting plasma glucose; SD, standard deviation.

Gliclazide is widely used in the treatment of type 2 diabetes, and it has been reported that CYP2C9 was a major contributor to gliclazide metabolic clearance with some contribution of CYP2C19. The existing evidence derived from pharmacokinetic studies carried out in healthy volunteers showed that CYP2C9*3 (rs1057910) was responsible for the majority of poor metabolizer phenotypes. There appeared to be great interindividual differences in the dose–response relationship for gliclazide, both with respect to the glucose and the insulin response. Monitoring of gliclazide plasma concentrations has therefore been proposed to reduce the cases of individual toxicity or lack of efficacy caused by relative overdosage or underdosage, respectively. A reduction in variability of plasma concentrations could be achieved if homozygous and heterozygous carriers of CYP2C9 allele *3 received lower doses. It is common sense in clinical pharmacology that a reduction in the variability of dose–concentration relationships could result in more predictable efficacy and lower incidence of adverse events. To achieve similar plasma concentration profiles, slow metabolizers (genotype CYP2C9*3/*3) should receive less than 50% of the dose that is adequate for rapid metabolizers. Carriers of the *3/*3 genotype of CYP2C9 might have a substantially higher rate of drug accumulation, particularly when a twice-daily dosing scheme is applied. Therefore, it is logical to hypothesize that patients with *3 alleles will have a lower clearance of SUs and a higher plasma SU levels, and this will eventually produce a better therapeutic response and a greater risk for hypoglycemia.

The existing evidence around a better therapeutic response of SUs as a result of CYP2C9 polymorphisms is scarce and inconclusive. A population pharmacogenetic study of incident sulfonylurea users found that type 2 diabetes patients with CYP2C9*2/*2, *2/*3, or *3/*3 genotypes were 3.4-fold (P = 0.0009) more likely to achieve a treatment hemoglobin A1C level <7% than patients with two wild-type CYP2C9 alleles, and this corresponded to a 0.5% (P = 0.003) greater reduction in hemoglobin A1C concentration. Another prospective study

### Table 1 | Comparison of baseline characteristics of the participants among different genotypes of rs1057910 in the present study

| Variable | Rs1057910 | P-value |
|----------|-----------|---------|
|          | AA (n = 672) | AC (n = 72) | CC (n = 2) |
| Age, years (SD) | 495 ± 8.2 | 503 ± 7.6 | 53.7 ± 6.9 |
| BMI, kg/m² (SD) | 247 ± 3.0 | 249 ± 2.8 | 250 ± 2.1 |
| Male (%) | 402 (59.8) | 45 (62.5) | 1 (50.0) |
| FPG, mmol/L (SD) | 113 ± 2.8 | 110.0 ± 2.6 | 105.5 ± 1.1 |
| Duration of diabetes, years (SD) | 1.26 ± 2.6 | 1.29 ± 2.1 | 1.23 ± 1.7 |
| Rice, g/day (SD) | 370 ± 130 | 370 ± 135 | 325 ± 65 |
| Exercise time, h/day (SD) | 0.9 ± 0.7 | 0.8 ± 0.7 | 0.5 ± 0.6 |
| Sugar | | | |
| None (%) | 455 (67.7) | 52 (72.3) | 2 (100.0) |
| 1–2/week (%) | 162 (24.2) | 14 (19.4) | 0 (0) |
| 3/week (%) | 55 (8.1) | 6 (8.3) | 0 (0) |

BMI, body mass index; FPG, fasting plasma glucose; SD, standard deviation.
Table 3 | Association of rs1057910 genotype with the therapeutic response to gliclazide in type 2 diabetes patients

| Rs1057910 | FPG \(^*\) | Change(per) \(^*\) |
|-----------|-------------|-----------------|
| AA (n = 672) | 8.3 (2.3) | 7.3 (1.8) | <0.001 |
| AC/CC (n = 74) | 3.0 (2.6) | 3.6 (2.2) | <0.001 |
| Change(per) (SD) | 24.5 (19.2) | 31.4 (14.9) | <0.001 |

\(^*\) After: after the gliclazide treatment; change(ab): the absolute value of FPG reduction; change(per): the percentage value of the FPG reduction.

from Japan yielded a similar result that the reduction in the hemoglobin A1C was significantly larger (P = 0.05) among the CYP2C9*1/*3 participants than that of the CYP2C9*1/*1 participants\(^{16}\). Whereas, if the decrease of FPG was taken as the outcome, two studies from the Netherlands found no significant difference in the decrease of FPG between carriers of CYP2C9*2 or CYP2C9*3 alleles and homozygous carriers of the CYP2C9*1 allele.\(^{17,32}\) In the present study, significantly different decreases of FPG resulting from polymorphism at rs1057910 were observed. Our study might not have an immediate impact on clinical practice; however, before such a model of care can be implemented, research is required to more clearly quantify the association of genetic variation with treatment outcomes and adverse effects.

As with all observational studies, there were limitations to the present study. We only studied the initial response to gliclazide for a short period, the association of CYP2C9*3 variant with the long-term response to gliclazide remains unknown and further studies with a longer follow-up period are worth considering. In addition, our study was carried out by use of a single-dose design. Further studies of patients with different CYP2C9*3 genotypes with multiple dosing will be required to verify the conclusions, and will be beneficial to the investigation of individual rational dosages and decreasing the risks of adverse effects.

The strengths of the present study include the prospective study design, relatively large sample size and the monotherapy of gliclazide. Like other cohort studies, the prospective design itself is an excellent method to control information bias. Compared with previous studies,\(^{13,20,29}\), our findings with 746 incident type 2 diabetes patients therefore provide relatively more powerful evidence for the association between CYP2C9*3 variant and the therapeutic response to gliclazide. The monotherapy of gliclazide avoids the influence of co-medication and the heterogeneous metabolism of SUs, as discussed above.

In conclusion, the results of the present study showed that polymorphism at rs1057910 significantly affected therapeutic response to gliclazide in type 2 diabetes patients. The risk allele is associated with greater decrease of FBG and a higher rate of treatment success with gliclazide monotherapy.

ACKNOWLEDGMENTS

We thank the staff of the Department of Endocrinology of the Second Affiliated Hospital of Shantou University Medical College for their support in the recruiting and management of the study participants.

DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

1. Aquilante CL. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther 2010; 8: 359–372.
2. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004; 64: 1339–1358.
3. Reis AF, Velho G. Sulfonylurea receptor -1 (SUR1): genetic and metabolic evidences for a role in the susceptibility to type 2 diabetes mellitus. Diabetes Metab 2002; 28: 14–19.
4. Kirchheiner J, Roots I, Goldammer M, et al. Effect of genetic polymorphisms in cytochrome p450 (CYP)2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005; 44: 1209–1225.
5. Niemi M, Cascorbi I, Timm R, et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002; 72: 326–332.
6. Lee HJ, Kim MS, Lee J, et al. Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics. J Clin Pharm Ther 2012; 37: 105–111.
7. Yoo HD, Kim MS, Cho HY, et al. Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects. Eur J Clin Pharmacol 2011; 67: 889–898.
8. Tan B, Zhang YF, Chen XY, et al. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. *Eur J Clin Pharmacol* 2010; 66: 145–151.

9. Kirchheiner J, Brockmoller J, Meineke I, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. *Clin Pharmacol Ther* 2002; 71: 286–296.

10. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. *Pharmacogenetics* 1996; 6: 341–349.

11. Kirchheiner J, Bauer S, Meineke I, et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. *Pharmacogenetics* 2002; 12: 101–109.

12. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. *Genet Med* 2005; 7: 97–104.

13. Holstein A, Plaschke A, Ptak M, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. *Br J Clin Pharmacol* 2005; 60: 103–106.

14. Klein J, Dolzan V, Janez A, CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphfonylurea treatment in type 2 diabetes patients. *Eur J Clin Pharmacol* 2014; 70: 421–428.

15. Zhou K, Donnelly L, Burch L, et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. *Clin Pharmacol Ther* 2010; 87: 52–56.

16. Suzuki K, Yanagawa T, Shibasaki T, et al. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. *Diabetes Res Clin Pract* 2006; 72: 148–154.

17. Becker ML, Visser LE, Trienekens PH, et al. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. *Clin Pharmacol Ther* 2008; 83: 288–292.

18. Holstein A, Hahn M, Patzer O, et al. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. *Eur J Clin Pharmacol* 2011; 67: 471–476.

19. Gokalp O, Gunes A, Carn H, et al. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. *Eur J Clin Pharmacol* 2011; 67: 1223–1229.

20. Ragia G, Petridis I, Tavridou A, et al. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. *Pharmacogenomics* 2009; 10: 1781–1787.

21. Ragia G, Tavridou A, Elens L, et al. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas. *Exp Clin Endocrinol Diabetes* 2014; 122: 60–63.

22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998; 15: 539–553.

23. Bell PA, Chaturvedi S, Gelfand CA, et al. SNPstream UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery. *Biotechniques* 2002; Suppl, 74, 76–77.

24. Feng Y, Mao G, Ren X, et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. *Diabetes Care* 2008; 31: 1939–1944.

25. Ren Q, Han X, Tang Y, et al. Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China. *Diabetologia* 2014; 57: 746–753.

26. Ji L, Ma F. China Guideline for Type 2 Diabetes (2010 edition). *Chin J Diabetes* 2012; 20: 81–117.

27. Elliot DJ, Suharjono Lewis BC, et al. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. *Br J Clin Pharmacol* 2007; 64: 450–457.

28. Manolopoulos VG. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. *Clin Chem Lab Med* 2007; 45: 801–814.

29. Huupponen R, Viikari J, Saarimaa H. Chlorpropamide and glibenclamide serum concentrations in hospitalized patients. *Ann Clin Res* 1982; 14: 119–122.

30. Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents: an update. *Clin Pharmacokinet* 1989; 16: 100–128.

31. Sartor G, Melander A, Schersten B, et al. Serum glibenclamide in diabetic patients and influence of food on the kinetics and effects of glibenclamide. *Diabetologia* 1980; 18: 17–22.

32. Swen JJ, Wassenaar JA, Krabben A, et al. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. *Pharmacogenomics* 2010; 11: 1517–1523.